Progress in TB preventive therapy

doi:10.3969/j.issn.1000-6621.2014.01.013

Abstract

LIU Er-yong, CHENG Shi-ming, LAI Yu-ji, WANG Dong-mei, LI Tao, WANG Li-ming, WANG Ni, XU Xiao-yu, ZHOU Lin. Progress in TB preventive therapy[J]. Chinese Journal of Antituberculosis, 2014, 36(1): 59-63. doi: 10.3969/j.issn.1000-6621.2014.01.013

References

［1］Corbett EL，Watt CJ,Maher D, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med, 2003,163(9): 1009-1021.
［2］［No authors listed］.Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med, 2000,161(4 Pt 2): S221-247.
［3］刘二勇，周林，成诗明.结核分枝杆菌潜伏性感染及预防性治疗研究进展的系统评价.中国防痨杂志，２０１３,３５（４）：231-238.
［4］Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc, 1970,26: 28-106.
［5］Ferebee SH, Mount FW. Chemotherapy of tuberculosis, progress and promise. Public Health Rep, 1957, 72(5): 412-420.
［6］Ferebee SH, Mount FW, Palmer CE. Tuberculosis prophylaxis trials in preview. Public Health Rep, 1957, 72(8): 703-704.
［7］Ferebee S, Mount FW, Anastasiades A. Prophylactic effects of isoniazid on primary tuberculosis in children; a preliminary report. Am Rev Tuberc, 1957, 76(6): 942-963.
［8］Comstock GW, Ferebee SH, Hammes LM, A controlled trial of community-wide isoniazid prophylaxis in Alaska. Am Rev Respir Dis, 1967, 95(6): 935-943.
［9］Ferebee SH, Mount FW. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. Am Rev Respir Dis, 1962, 85: 490-510.
［10］Lobue P, Menzies D. Treatment of latent tuberculosis infection: an update. Respirology, 2010, 15(4): 603-622.
［11］Mount FW， Ferebee SH.The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis. Am Rev Respir Dis, 1962, 85: 821-827.
［12］Ferebee SH,Mount FW,Murray FJ, et al. A controlled trial of isoniazid prophylaxis in mental institutions. Am Rev Respir Dis, 1963, 88:161-175.
［13］Grzybowski S, Ashley MJ,mckinnon NE,et al. In Canada: a trial of chemoprophylaxis in inactive tuberculosis. Can Med Assoc J, 1969, 101(9): 81-86.
［14］Grzybowski S, Ashley MJ, Pinkus G. Chemoprophylaxis in inactive tuberculosis: long-term evaluation of a Canadian trial. Can Med Assoc J, 1976, 114(7): 607-611.
［15］Snider DE Jr, Caras GJ, Koplan JP. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA, 1986, 255(12):1579-1583.
［16］［No authors listed］.Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ, 1982, 60(4): 555-564.
［17］［No authors listed］.Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep, 2000, 49(RR-6): 1-51.
［18］Long R. The Canadian Lung Associsation/Canadian Thoracic Society and tuberculosis prevention and control. Can Respir J, 2007, 14(7):427-431.
［19］Menzies D, Jahdali H Al,Otaibi B Al. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res, 2011, 133(3):257-266.
［20］Comstock GW,Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis, 1979, 119(5):827-830.
［21］Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis, 1999, 3(10): 847-850.
［22］Selwyn PA,Hartel D,Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med, 1989, 320(9): 545-550.
［23］Akolo C,Adetifl I,Shepperd S,et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev, 2010,20(1): CD000171.
［24］Cain KP,McCarthy KD,Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med, 2010, 362(8):707-716.
［25］World Health Organization.Policy statement on preventive therapy against tuberculosis in people living with HIV. Geneva: World Health Organization Global Tuberculosis Programme, Joint United Nations Programme on HIV/AIDS, 1998.
［26］World Health Organization.Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resourceconstrained settings. Geneva:World Health Organization,2011.
［27］Martinson NA,Barnes GL,Moulton LH, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med, 2011, 365(1): 11-20.
［28］Balcells ME, Thomas SL,godfrey-faussett P,et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis, 2006, 12(5): 744-751.
［29］Kopanoff DE, Snider DE Jr, Caras GJ. Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. Am Rev Respir Dis, 1978, 117(6):991-1001.
［30］Nolan CM, Goldberg SV, Buskin SE. Hepatotoxicity associa-ted with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA, 1999, 281(11): 1014-1018.
［31］LoBue PA, Moser KS. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med, 2003, 168(4): 443-447.
［32］Lecoeur HF, Truffot-Pernot C, Grosset JH. Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. Am Rev Respir Dis, 1989, 140(5):1189-1193.
［33］Gao XF,Wang L,Lin GJ, et al. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. Int J Tuberc Lung Dis, 2006, 10(10):1080-1090.
［34］Gordin F,Chaisson RE,Matts JP, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study Group. JAMA, 2000, 283(11):1445-1450.
［35］Halsey NA,Coberly JS,Desormeaux J, et al., Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. Lancet, 1998, 351(9105):786-792.
［36］Ijaz K,Jereb JA,Lambert LA, et al. Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis, 2006, 42(3):346-355.
［37］Centers for Disease Control and Prevention,American Thoracic society.Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. MMWR Morb Mortal Wkly Rep, 2003, 52(31):735-739.
［38］Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis, 2010, 14(11): 1374-1381.
［39］Schechter M, Zaidenverq T,falco G,et al. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. Am J Respir Crit Care Med, 2006, 173(8):922-926.
［40］Sterling TR, Villarino ME,Borisov AS,et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med, 2011, 365(23): 2155-2166.
［41］Centers for Disease Control and Prevention.Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep, 2011, 60(48):1650-1653.
［42］Dorman SE，Johnson JL,Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med, 2009, 180(3): 273-280.

[1]	Li Yang, Sun Feng, Zhang Wenhong. Short-course treatment for tuberculosis: past achievements and future directions [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 991-997.
[2]	Wang Xueyu, Shi Wenhui, Li Qi, Jing Wei, Chu Naihui, Nie Wenjuan. Efficacy and safety of Baidiziyin Pill and Shenqiyifei Pill in adjuvant treatment of susceptible pulmonary tuberculosis patients: a national randomized controlled multicenter clinical study [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1306-1312.
[3]	Fu Liang, Deng Guofang. MDR-Chin study analysis: prospects of using all-oral short-course treatment regimens for multidrug-resistant pulmonary tuberculosis in China [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 18-22.
[4]	Zhou Feng, Li Tongxin, Yang Song, Tang Shenjie. Progress on short-course regimens for the treatment of tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(3): 311-317.
[5]	Ge Qiping, Zhang Lijie, Huang Xuerui, Jiang Guanglu, Han Xiqin, Wang Jingping, Du Jian, Ma Yan, Gao Weiwei. Effect of a new treatment regimen on patients with initially retreated drug-sensitive pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(11): 1078-1083.
[6]	Gao Dan, Wang Linghua, Huang Jinpeng, Zhang Yue, Mao Xiaoxiao. Analysis of the application effect of integrated traditional Chinese and Western medicine pulmonary rehabilitation nursing program for patients with tuberculous empyema undergoing thoracoscopic clearance [J]. Chinese Journal of Antituberculosis, 2023, 45(10): 940-948.
[7]	Gao Dan, Wang Linghua, Huang Jinpeng, Zhang Yue, Mao Xiaoxiao. Construction of pulmonary rehabilitation nursing program of integrated traditional Chinese and Western medicine for patients with tuberculous empyema under thoracoscopic clearance [J]. Chinese Journal of Antituberculosis, 2023, 45(10): 932-939.
[8]	Wang Yuxiang, Chen Qiuqi, Yu Xinxin, Zhan Senlin, Zhang Peize, Deng Guofang. 3HP regimen in the treatment of rheumatic diseases complicated with Mycobacterium tuberculosis latent infection:a prospective study [J]. Chinese Journal of Antituberculosis, 2022, 44(9): 906-910.
[9]	Jin Long, Wang Lihua, Zhang Xiaolei, Jiang Huailong, Li Xiaonan, Liu Yuqin. Efficacy and safety of modified all-oral short course chemotherapy in the treatment of multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(12): 1321-1326.
[10]	Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 Edition) [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 859-866.
[11]	ZHOU Wen-qiang, ZHANG Shuang, CHU Nai-hui. Current status and prospect of all-oral treatment regimens for drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 879-882.
[12]	LIAO Wei-ming, FU Liang, DENG Guo-fang, YUAN Xiao-liang. Research progress of bedaquiline for the treatment of multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(6): 619-624.
[13]	GE Qi-ping*, DU Jian, SHU Wei, MA Yan, MA Li-ping, ZHAO Cai-yan, CHEN Yu-hui, ZHANG Li-jie, HUANG Xue-rui, HAN Xi-qin, CHEN Sheng-yu, WANG Fei, LI Bo, CAO Wen-li, LIU Qian-ying, CHEN Dong-jin, SHI Lian, WANG Xin, LI You-lun, YANG Shang-peng, PENG Zhang-li, WU Chao, OUYANG Bing, WANG Fu-rong, LI Po, WU Xiang, XI Xiu-e, LENG Xue-yan, ZHANG Hai-qing, LI Hua, LI Juan, YANG Cheng-qing, ZHANG Peng, CUI Hong-zhe, XIE Li, LIU Yu-hong, LI Liang, GAO Wei-wei. Treatment effect analysis of the optimized regimen for re-treated drug-susceptible pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 328-334.
[14]	Shanghai Clinical Research Center for Infectious Disease (Tuberculosis)/Shanghai Pulmonary Hospital, Tongji University School of Medicine, Beijing Chest Hospital , Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus on the diagnosis and treatment of retreatment pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1226-1238.
[15]	HE Xiao-xin, LI Bo, ZHOU Lin. Interpretation of Four-month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(12): 1243-1247.